Shandong Xinhua Pharmaceutical

What Shandong Xinhua Pharmaceutical does

Shandong Xinhua Pharmaceutical (山东新华制药股份有限公司) is a Chinese pharmaceutical manufacturer founded in 1943 as a state-owned enterprise in Zibo, Shandong, and now publicly listed on the Shenzhen Stock Exchange under ticker 000756.SZ. The company employs 5,001-10,000 people and operates as China's leading ibuprofen manufacturer, producing active pharmaceutical ingredients (APIs), finished dosage forms, and pharmaceutical intermediates. Its product portfolio spans the legacy ibuprofen franchise, established products such as Sevelamer carbonate tablets, export products including high-purity EPA ethyl ester soft capsules, and a pipeline of small molecule drug candidates (LXH-2101, LXH-2102, and LXH-2103 injection, with the latter receiving NMPA clinical trial approval in June 2026).

The company's underlying technology centers on small molecule pharmaceutical development and pharmaceutical intermediate synthesis, with proprietary pipeline candidates advancing through discovery and clinical trial phases. Its business model is anchored in pharmaceutical manufacturing and sales, generating revenue through one-time license/manufacturing transactions via domestic distribution networks in China and export partnerships for international markets. Distribution is executed through direct sales to enterprise customers domestically, while international expansion relies on strategic partnerships — most notably with Sinovac Biotech, which handles distribution of EPA ethyl ester soft capsules to Saudi Arabia and the UAE, and previously collaborated on Sevelamer carbonate tablets for Middle Eastern markets.

The company's primary customer segment is the broader pharmaceutical industry, with use cases spanning ibuprofen and intermediate manufacturing and raw material drug production, and a secondary segment covering international pharmaceutical markets via export. Pricing is not publicly disclosed. Recent operating performance reflects industry-wide headwinds: a 5.3% net profit decline in 2024 and a sharper 26% YoY decline in Q1-Q3 2025 (net profit of 256.2 million yuan) have been attributed to oversupply and weakening demand in the domestic drug market, prompting a strategic emphasis on international expansion and pipeline diversification.

Name

Shandong Xinhua Pharmaceutical

Legal name

山东新华制药股份有限公司

Website

https://xhzy.com

Company type

Public

Founded year

1943

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Shandong Xinhua Pharmaceutical is China's leading ibuprofen manufacturer, founded in 1943 and publicly listed on the Shenzhen Stock Exchange. It produces APIs, finished dosage forms, pharmaceutical intermediates, and a small molecule drug pipeline, with growing exports to Middle Eastern markets via Sinovac partnership.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD)

Keywords

• Pharmaceutical manufacturing
• Ibuprofen production
• Active pharmaceutical ingredients
• Small molecule drugs
• Generic pharmaceuticals

Headquarters

HQ city

Zibo

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Manufacturing and Sales: Primary revenue from manufacturing and selling pharmaceutical products including ibuprofen (market leader in China), raw material drugs, and pharmaceutical intermediates. Revenue generated through domestic sales and export of pharmaceutical products to international markets.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Shandong Xinhua Pharmaceutical manufactures and sells pharmaceutical products, primarily as China's leading ibuprofen producer. Its portfolio includes raw material drugs (APIs), pharmaceutical intermediates, finished dosage forms (EPA ethyl ester soft capsules, Sevelamer carbonate tablets), and a pipeline of small molecule drug candidates (LXH-2101, LXH-2102, LXH-2103) approved by China's NMPA for clinical trials.

Product overview

Shandong Xinhua Pharmaceutical is a pharmaceutical manufacturer offering a portfolio of drug products including small molecule drug candidates in development (LXH-2101, LXH-2102, LXH-2103), established pharmaceutical products (ibuprofen, Sevelamer carbonate tablets), and export products (EPA ethyl ester soft capsules). The company operates in both domestic Chinese and international markets, with recent partnerships focused on Middle Eastern pharmaceutical exports.

Differentiator

Problem solved

Functional benefit

Products and services

• Ibuprofen
• Eicosapentaenoic acid (EPA) ethyl ester soft capsules
• Sevelamer carbonate tablets
• LXH-2103 injection
• LXH-2101
• LXH-2102
• Pharmaceutical intermediates and raw material drugs (APIs)

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Sinovac BiotechcoreStrategic or Co-development Partner · 13 July 2026Sinovac Pharmaceutical partnered with Xinhua Pharmaceutical (000756.SZ) to export high-purity eicosapentaenoic acid (EPA) ethyl ester soft capsules to Saudi Arabia and the UAE. This is their second major partnership, following earlier collaboration on Sevelamer carbonate tablets. Both companies seek to expand domestically-produced pharmaceuticals into key Middle Eastern markets.

Scale indicators3 records

Recent moves5 records

Expansion highlights1 record

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/shandong-xinhua-pharmaceutical-company-limited

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shandong Xinhua Pharmaceutical